TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1932652

Group type: EXPERIMENTAL
Intervention: Cardioplegic solution enriched with creatine phosphate (10 mmol/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cardioplegic solution
Number of subjects: 40
Study: 6699308

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31658994

Group type: EXPERIMENTAL
Intervention: Ipilimumab with concurrent stereotactic radiation therapy (50 Gy in 4 fractions)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with sequential stereotactic radiation therapy (60 Gy in 10 fractions)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-dose radiation to nontargeted lesions
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with radiation (overall)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sequential lung group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with radiation (liver metastases)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with radiation (lung metastases)
Number of subjects: 106
Study: 29464585

Group type: EXPERIMENTAL
Intervention: 19-gauge histology needle (PC19)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 19-gauge standard needle (EC19)
Number of subjects: 110
Study: 26934128

Group type: EXPERIMENTAL
Intervention: Premixed insulin lispro protamine suspension 75%/insulin lispro solution 25% (LM25) twice daily (bid)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Basal insulin glargine plus prandial insulin lispro (IGL), once daily
Number of subjects: 476
Study: 24518147

Group type: EXPERIMENTAL
Intervention: Early physical rehabilitation program (EPRP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study: 23046566

Group type: EXPERIMENTAL
Intervention: JUC (nanotechnology antimicrobial spray)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 1150
Study: 20167143

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 micrograms x 2 inhalations (320/9 micrograms; n = 124)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Budesonide DPI 200 micrograms x 2 inhalations (400 micrograms; n = 63)
Number of subjects: 187
Study: 21707149

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15947981

Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg; study group: n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group: n=20)
Number of subjects: 40
Study: 11812509

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.2, 0.4, and 0.8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: D-amphetamine (15 mg, oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9509076

Group type: COMPARATOR
Intervention: Insulin-tolerance test (ITT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Arg stimulation test (Arg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Minor heat exposure before the ITT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Admission to hospital on the morning of the test
Number of subjects: 22

Group type: COMPARATOR
Intervention: Plasma glucagon response
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Plasma glucagon response after hospital admission
Number of subjects: 22

Group type: COMPARATOR
Intervention: Serum cortisol response
Number of subjects: 22
Study: 7980356

Group type: EXPERIMENTAL
Intervention: In vivo exposure to various fear domains (heights, transportation, social situations)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: In vivo exposure sessions
Number of subjects: 25
Study: 2647495

Group type: EXPERIMENTAL
Intervention: gallopamil 50 mg t.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gallopamil 75 mg t.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29174683

Group type: EXPERIMENTAL
Intervention: HZ/su administered 0, 6-month schedule
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: HZ/su administered 0, 12-month schedule
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control group (0, 2-month schedule)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: All dosing intervals
Number of subjects: 354
Study: 26294706

Group type: EXPERIMENTAL
Intervention: Integrated mental health and substance abuse treatments for at least the first 3 years
Number of subjects: 150
Study: 25763129

Group type: EXPERIMENTAL
Intervention: Standardized prerecorded video program on weight reduction
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comprehensive weight reduction program
Number of subjects: 130
Study: 23608784

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 571
Study: 20736036

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 19102187

Group type: EXPERIMENTAL
Intervention: Manipulative reduction plus lumbar traction and various physiotherapies
Number of subjects: 11128

Group type: COMPARATOR
Intervention: Lumbar traction and various physiotherapies
Number of subjects: 11128
Study: 16902796

Group type: COMPARATOR
Intervention: High-carbohydrate low-fat diet (HC)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet with additional fat (HCF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Simulated 20-km time-trial after both diets
Number of subjects: 11
Study: 12828749

Group type: EXPERIMENTAL
Intervention: TL-01 UVB
Number of subjects: 28

Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 28
Study: 11024413

Group type: EXPERIMENTAL
Intervention: Focal confluent laser photocoagulation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 70
Study: 8711648

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (for indomethacin study)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (for ipratropium study)
Number of subjects: 31
Study: 1352428

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1% instilled one hour before and immediately after laser treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Apraclonidine 1% delivered only after trabeculoplasty
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 60
Study: 6725520

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/kg oral clonidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5.0 micrograms/kg oral clonidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30103220

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Multidose Azithromycin
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Single-dose Azithromycin
Number of subjects: 981
Study: 29889157

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 276
Study: 27344826

Group type: EXPERIMENTAL
Intervention: Moving cupping at Hechelu combined with rubbing method
Number of subjects: 216

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride capsules (oral administration, once a day for 4 weeks)
Number of subjects: 216
Study: 25012999

Group type: EXPERIMENTAL
Intervention: Task-specific training conducted by physical therapists in participants' homes, focusing on walking, sit-to-stand transfers, and standing, twice a week for 8 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 30
Study: 22270977

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sibling support
Number of subjects: 59
Study: 20484057

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day for 6 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 18584574

Group type: EXPERIMENTAL
Intervention: Levetiracetam (2000 mg daily for 10 weeks)
Number of subjects: 20
Study: 15975721

Group type: EXPERIMENTAL
Intervention: Veno-venous continuous renal replacement therapy (CRRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 12468480

Group type: EXPERIMENTAL
Intervention: Informing participants of their treatment allocation at trial closure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Not informing participants of their treatment allocation at trial closure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reasons for not informing participants
Number of subjects: 120
Study: 9799054

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole p.o. once daily for 11 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7617798

Group type: EXPERIMENTAL
Intervention: Oral ethanol (1.1 ml/kg 95% ethanol as a 20% solution)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous yohimbine (0.4 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined administration of ethanol and yohimbine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2612797

Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 325238

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (50 or 100 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Codeine sulfate (30 or 60 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31606897

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 370

Group type: COMPARATOR
Intervention: Apixaban 5 mg twice daily
Number of subjects: 370
Study: 30389745

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (not specified in detail)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Weight loss intervention in children and adolescents (Maintain-Children)
Number of subjects: 143
Study: 28374923

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 2 g/day for 9 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (unsupplemented group, UG)
Number of subjects: 22
Study: 26001913

Group type: EXPERIMENTAL
Intervention: Manualised, multimodal group psychotherapy based on integrative psychotherapy (IPT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Self-help groups
Number of subjects: 172
Study: 23617452

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Empagliflozin 200 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21718491

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) administered 4 hours prior to ischemia
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) administered 48 hours prior to ischemia
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 23
Study: 19853621

Group type: EXPERIMENTAL
Intervention: Project STRIDE
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Step into Motion
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control (for STRIDE)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control (for SIM)
Number of subjects: 488
Study: 17329302

Group type: EXPERIMENTAL
Intervention: 20 mg buspirone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg buspirone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15370866

Group type: EXPERIMENTAL
Intervention: Real-time electromyographic feedback
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acceleration index delivered verbally post-lift
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no feedback training)
Number of subjects: 28
Study: 11236537

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (30 Gy in 24 fractions over 5 weeks with a pelvic boost to 50 Gy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Postoperative chemotherapy (six series of polychemotherapy with cisplatin 50 mg/m2, adriamycin 50 mg/m2, and cyclophosphamide 500 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 150
Study: 9308063

Group type: EXPERIMENTAL
Intervention: 70% N2O, 30% O2 and halothane
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 70% N2O, 30% O2, halothane and 2 micrograms.kg‐1 fentanyl
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 70% N2O, 30% O2 and 10 micrograms.kg‐1 fentanyl
Number of subjects: 66
Study: 8286880

Group type: EXPERIMENTAL
Intervention: Iron supplementation (39 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study: 2424279

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5,000 IU X 2 s.c.) started preoperatively and continued daily for one week post-operatively
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Per-operative electrical calf muscle stimulation with groups of impulses plus post-operative dextran infusions every other day for one week
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (without prophylaxis)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Patients with intracranial neoplasms
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Patients with intracranial vascular disease
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Patients with spinal diagnoses
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Paretic lower limbs in cranial diagnoses
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Paretic limbs in spinal disorders
Number of subjects: 122
Study: 30784726

Group type: EXPERIMENTAL
Intervention: Low field magnetic stimulation (LFMS) - three 20-min sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham LFMS treatment
Number of subjects: 30
Study: 29509864

Group type: EXPERIMENTAL
Intervention: PSA screening intervention
Number of subjects: 415357

Group type: COMPARATOR
Intervention: Standard practice (unscreened)
Number of subjects: 415357
Study: 26220547

Group type: EXPERIMENTAL
Intervention: 4Weeks2Freedom
Number of subjects: 3019

Group type: EXPERIMENTAL
Intervention: Informational film
Number of subjects: 3019

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 3019
Study: 23907736

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy during dental restorations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no biofeedback therapy)
Number of subjects: 40
Study: 22559218

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 0
Study: 20130470

Group type: EXPERIMENTAL
Intervention: Mifepristone 75 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mifepristone 150 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mifepristone 225 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mifepristone (all doses)
Number of subjects: 57
Study: 17335685

Group type: EXPERIMENTAL
Intervention: Thalidomide as maintenance therapy after double ASCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of conventional chemotherapy with novel agents (thalidomide or bortezomib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myeloablative conditioning regimens before allogeneic stem cell transplantation
Number of subjects: 0
Study: 16244539

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation ON
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sacral nerve stimulation OFF
Number of subjects: 34
Study: 12702936

Group type: EXPERIMENTAL
Intervention: GSPECT
Number of subjects: 37
Study: 10825326

Group type: EXPERIMENTAL
Intervention: Ephedrine 30 mg IV
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ephedrine 10 mg IV
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ephedrine 20 mg IV
Number of subjects: 80
Study: 8982294

Group type: EXPERIMENTAL
Intervention: BC-PCs (pooled buffy coats)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SD-PCs (single donor apheresis)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (random donor platelet transfusions)
Number of subjects: 32
Study: 1430132

Group type: EXPERIMENTAL
Intervention: RU 486 treatment for 12 hours
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RU 486 treatment for 24 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 6494068

Group type: EXPERIMENTAL
Intervention: Topical steroids (six different potencies), applied once daily without occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical steroids (six different potencies)
Number of subjects: 0
Study: 2883906

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metoprolol 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxprenolol 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no beta-adrenoreceptor antagonist)
Number of subjects: 30
Study: 30160643

Group type: EXPERIMENTAL
Intervention: Aerobic activity
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Aqua fitness
Number of subjects: 347
Study: 29237465

Group type: EXPERIMENTAL
Intervention: Complete semirigid ring (SR)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Flexible band (FB)
Number of subjects: 171
Study: 26169045

Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (AA genotype)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (AA genotype)
Number of subjects: 183
Study: 23311602

Group type: EXPERIMENTAL
Intervention: MEAW technique with modified Class III elastics from maxillary mini-implants
Number of subjects: 20

Group type: COMPARATOR
Intervention: MEAW and long Class III elastics from upper second molars
Number of subjects: 20
Study: 21638181

Group type: EXPERIMENTAL
Intervention: Diaphragmatic injection of bupivacaine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Topical wash with bupivacaine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (sham injection and sham wash)
Number of subjects: 128
Study: 18495379

Group type: EXPERIMENTAL
Intervention: Non closure of the peritoneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closure of the peritoneum
Number of subjects: 0
Study: 16510266

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) activated
Number of subjects: 4

Group type: COMPARATOR
Intervention: Vagus nerve stimulation (VNS) de-activated
Number of subjects: 4
Study: 14692130

Group type: EXPERIMENTAL
Intervention: Combined spinal, epidural and general anesthesia (CSEGA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 67
Study: 11193132

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate aerosol (1.25 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sublingual isosorbide dinitrate tablet (5 mg)
Number of subjects: 40
Study: 9196354

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (half the dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (400-909 micrograms/m2/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Budesonide (high doses)
Number of subjects: 34
Study: 1350400

Group type: EXPERIMENTAL
Intervention: Superficial radiotherapy (SRT) - three fractionated doses of 150 cGy (90 kV, 5 mA, 1.00 mm aluminium filter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Superficial radiotherapy (SRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 3709993

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 8
Study: 30133478

Group type: EXPERIMENTAL
Intervention: NASVAC (therapeutic vaccine containing HBsAg and HBcAg, 100 μg each, administered in 2 cycles of 5 doses)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: NASVAC
Number of subjects: 160

Group type: COMPARATOR
Intervention: Peg‐IFN (48 subcutaneous injections of Peg‐IFN alfa 2b, 180 μg per dose, every week for 48 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Peg‐IFN
Number of subjects: 160
Study: 26728480

Group type: EXPERIMENTAL
Intervention: PPV plus oral low‐dose CPA (50 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: PPV alone
Number of subjects: 70
Study: 24361201

Group type: EXPERIMENTAL
Intervention: Medicare's nonpayment policy for catheter-associated urinary tract infections (CAUTIs) implemented in October 2008
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various hospital characteristics
Number of subjects: 0
Study: 22832839

Group type: EXPERIMENTAL
Intervention: Inhalatory/Epidural Anesthesia (IPA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Inhalatory/Endovenous Anesthesia (IEA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both IPA and IEA
Number of subjects: 17
Study: 20658822

Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch (35 mg)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 17854434

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for relapse prevention
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for smoking cessation
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 302
Study: 16288408

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin combination treatment
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Didanosine use
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Elevated total bilirubin level
Number of subjects: 383
Study: 12881158

Group type: EXPERIMENTAL
Intervention: Cardiotomy suction
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cell-saver
Number of subjects: 33